We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
2084-P: Sustained Weight Loss in Men with Hypogonadism and Type 2 Diabetes (T2DM) Receiving Long-Term Treatment with Injectable Testosterone Undecanoate (TU): Ten-Year Data from a Urological Registry Study.
- Authors
HAIDER, AHMAD; HAIDER, KARIM S.; SAAD, FARID
- Abstract
Background: Testosterone is inversely correlated with weight and waist circumference (WC). Methods: Of 324 men with hypogonadism and T2DM in a registry, 257 (79.3%) were obese, 60 (18.5%) overweight and 7 (2.2%) had normal weight. 152 received TU 1000 mg/12 weeks (T-group), 172 opted against treatment (CTRL). Changes over time between groups were compared by mixed effects model for repeated measures with random effect for intercept and fixed effects for time, group and their interaction, and adjusted for age, weight, WC, fasting glucose, blood pressure, lipids and quality of life to account for baseline differences between the two groups. Results: Mean age: 62.7±5.1, follow-up: mean: 7.9, median: 9 years. T-group: weight decreased by 21.4±0.5 kg at 10 years. CTRL: weight increased by 4.8±0.4 kg. Estimated adjusted difference between groups: 26.2 kg (p<0.0001 for all). T-group: WC decreased by 12.8±0.4 cm at 10 years. CTRL: WC increased by 5.6±0.4 cm, difference between groups: 18.4 cm (p<0.0001 for all). T-group: BMI decreased by 6.9±0.2 kg/m² at 10 years. CTRL: BMI increased by 1.5±0.1 kg/m², difference between groups: 8.4 kg/m² (p<0.0001 for all). Weight loss was 18.8±0.4% in the T-group and weight gain 5.5±0.3% in CTRL, difference between groups: 24.3% (p<0.0001 for all). T-group: waist:height ratio decreased by 0.07±0.00 at 10 years. CTRL: waist:height ratio increased by 0.03±0.00, difference between groups: 0.10 (p<0.0001 for all). T-group: Visceral adiposity index (VAI) decreased by 2.5±0.2. CTRL: VAI increased by 2.5±0.2, difference between groups: 5.0 (p<0.0001 for all). Since injections were administered in the office and documented, there was a 100% adherence to testosterone therapy. Conclusions: Long-term testosterone therapy with TU in men with hypogonadism and T2DM sustainably improved anthropometric measures which worsened in untreated controls. Disclosure: A. Haider: Research Support; Self; Bayer AG. Speaker's Bureau; Self; Bayer AG. K.S. Haider: Speaker's Bureau; Self; Bayer AG. F. Saad: Employee; Self; Bayer AG. Stock/Shareholder; Self; AbbVie Inc., Amgen Inc., Bayer AG. Funding: Bayer AG
- Publication
Diabetes, 2019, Vol 68, pN.PAG
- ISSN
0012-1797
- Publication type
Article
- DOI
10.2337/db19-2084-P